You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Skyline will use TrovaGene's nucleophosmin protein mutation, which is found in around 35 percent of acute myeloid leukemia patients and is associated with good disease prognosis, in its Affymetrix-manufactured AMLprofiler in vitro diagnostic.
Skyline Diagnostics will use the NPM1 biomarker technology in a microarray testing service to stratify AML patients.
TrovaGene is developing molecular diagnostics based on its transrenal nucleic acid technology.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.
